Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14465907 | 0.84 | SMN1; SMN2 (0.57) | ALDH1A1MEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL2939798 | 0.84 | MAPT (0.42) | MAPTHRH3ALDH1A1MEN1KMT2A | |
| SCHEMBL25067239 | 0.79 | TP53 (0.42) | MAPTHRH3ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL13981343 | 0.79 | MAPT (0.67) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22461356 | 0.78 | HRH3 (0.41) | MAPTHRH3ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL1296764 | 0.78 | TSHR (0.43) | ALDH1A1KMT2ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL2657918 | 0.78 | — | — | |
| SCHEMBL23396158 | 0.78 | HRH3 (0.50) | MAPTHRH3ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL16643864 | 0.77 | MEN1 (0.50) | HRH3ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12531876 | 0.77 | MEN1 (0.46) | HRH3ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | MAPT 2399/4885HRH3 141/4885ALDH1A1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.